EMCC Roundup

Astex Pharmaceuticals Inc., of Dublin, Calif., said that its HSP90 inhibitor, AT13387, showed activity in in vitro gastrointestinal stromal tumor (GIST) models. The compound was more active than 17-AAG, a first-generation HSP90 inhibitor, in all cell lines tested.